Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Roswell Park's Dr. Gal Shafirstein / Simphotek Project

<< Previous

Bullboard Posts

Next >>

Comment by StevenBirchon Feb 17, 2022 8:41am

608 Views

Post# 34437360

RE:RE:RE:Roswell Park's Dr. Gal Shafirstein / Simphotek Project

Thaks as usual CS, Enrique and Eog.

I agree and think NMIBC was chosen as the best entry point and not downplaying it for either the people who have it or the value to the company but it seems the biggest and best is yet to come. I was disappointed with the notion of competition being behind the 'sell-off' this week as there is very little volume to back it up, I think it's just the uausal pattern. When you account for everything that they have going on there doesn't seem to be any competition or am I wrong?

CancerSlayer wrote:

enriquesuave wrote: Nice find Eoganacht. Theralase seems to be going with X-ray activation of Rutherin rather than IO ( intraoperative ie during open surgery) with Photofrin at Roswell. I guess both applications could be trialed, but maybe they first want to use X-ray activation which is way more appealing as no need for surgery and perhaps to replace surgery altogether. They are showing a 3 log kill in vitro for human NSCLC. That is 99.9% Tumor destruction, so even if it's just 90% in vivo, then we have a winner IMO. Imagine 90% Tumor destruction repeated over 3-6 months, and add to that the immune response possibly enhanced by Merck's checkpoint inhibitor Keytruda. Who knows, I just can't wait for them to start that NSCLC trial and for more NMIBC data.

Thanks for that info Enrique...Any ability to use non-invasive X-ray PDT with Rutherrin in NSCLC would further highlight the versatility of this ACT & give TLT a tremendous advantage over the competition. That in vitro kill rate bodes well for a potential in vivo cure imo for the smaller-sized tumors.

Additionally, an X-PDT approach can not only potentially replace surgery, it could likely be used preoperatively for more advanced cases to reduce the tumor burden & the extent of surgery required, improve overall operability, & ultimately improve surgical success...all the while stimulating an immune response with or w/o the help of a checkpoint inhibitor. I would also think repeated X-PDT treatments could readily be used to potentially reduce or even eliminate any need for other adjuvant therapies.

Very excited to see this ACT/Rutherrin move into the clinical stages for NSCLC, which is a "much bigger" performance stage than either NMIBC or GBM.